RNS Reach - non-regulatory
announcement
16 January 2025
SEED Innovations
Limited
("SEED" or the
"Company")
2025 New Year
Statement
Driving shareholder value through
strategic portfolio management
SEED Innovations Ltd, an AIM-listed investment
firm providing access to high-growth, disruptive life sciences and
technology ventures typically out of reach for everyday investors,
is pleased to share a 2025 New Year Statement from its CEO, Ed
McDermott.
"As we move into the new year, I reflect on a
difficult 2024, which saw many challenges but also some strides
forward including the delivery of positive results from SEED's
largest portfolio companies and the second instalment of proceeds
from the sale of Leap Gaming received in April 2024. This enabled
us to reward our shareholders with a share buyback programme and an
inaugural special dividend.
"We expect 2025 to be somewhat more dynamic as
we continue to actively manage our portfolio, encompassing liquid
and longer term opportunities. To support this, we are
currently conducting due diligence on several promising prospects
across a range of sectors.
"Our short-term trading strategy will remain
industry-agnostic, while our traditional venture strategy will
continue prioritising seeking significant returns on larger
investment sums. There continues to be a substantial capital
deficit to meet the needs of growth companies globally, which has
caused innovation to take a step back in recent years. However, I
see the next 2-3 years as an opportune time to accelerate the
growth of carefully selected ventures with the potential to scale
into meaningful exits, ideally within 24 months of
investment.
"Despite projections of low growth for the UK
in the coming years, there are still sectors of considerable
interest. For instance, in fintech, regulatory and compliance
demands are driving significant expenditure from major
institutions.
"As mentioned, our portfolio companies
continue to move forward despite the challenges of raising
capital.
·
Clean Food Group: Raised c.£2.5m in March 2024 at SEED's
carrying value of 16.5p per share, supporting our valuation.
Furthermore, it announced a partnership with THG Labs (part of The
Hut Group) in October, hinting at further development of its
strategy, which we hope may be followed by a further uplift in
valuation in 2025.
·
Inveniam: Announced a significant partnership in December
with, and investment from, a leading global AI investor, G42.
Whilst details of the investment by G42 have not yet been made
public, we are hopeful that this will translate into a modest
uplift in the carrying value of Inveniam at the next valuation
point.
·
Little Green Pharma: Continued its growth with a company
record-breaking half year performance announced in November. In
December, it announced plans to acquire HH (Australia) Pty Ltd,
which operates a nationally focused medicinal cannabis distribution
business across Australia aligning with its strategy of
capitalising on current market conditions to acquire sustainable
medicinal cannabis businesses at attractive valuations.
·
Juvenescence: Advanced its portfolio of companies focused on
longevity, positioning it for success in this fast-growing
healthcare landscape.
·
Avextra: Announced a €3.3m fundraise early in 2024 at above
SEED's carrying value, supporting our carrying value.
"In addition, a new investment made in August
in Pantheon Resources, as part of SEED's short-term trading
strategy, resulted in a successful exit in November, yielding a 35%
profit or approximately £87k.
"Regarding our market performance, our current
market capitalisation is approximately £3.18m, while as of
November, our cash reserves alone exceeded £3.8m, and our net asset
value ('NAV') was estimated at £10.6m as of 30 September 2024.
These figures clearly indicate that we are trading at a significant
discount to our intrinsic value.
"With a robust cash reserve, coupled with our
dynamic portfolio and promising investment pipeline, I am confident
that 2025 will be a year of significant progress for SEED. I would
like to extend my thanks to our team and shareholders for their
unwavering support as we work towards unlocking SEED's full
potential and aligning its stock valuation with the value of its
assets.
"Wishing you all a prosperous and successful
2025."
Ed McDermott, CEO
- Ends -
For further information please
visit: www.seedinnovations.co
or contact:
Ed McDermott
Lance de Jersey
|
SEED Innovations
Ltd
|
info@seedinnovations.co
|
James Biddle
Roland Cornish
|
Beaumont Cornish Limited,
Nomad
|
(0)20 7628 3396
|
Isabella Pierre
Damon Heath
|
Shard Capital Partners
LLP
Broker
|
(0)20 7186 9927
|
Ana Ribeiro
Isabel de Salis
Seb Weller
|
St Brides Partners
Ltd,
Financial PR
|
seed@stbridespartners.co.uk
|
Notes
Seed Innovations Ltd
SEED Innovations is an AIM quoted
investment company focused primarily on disruptive high growth life
sciences and technology businesses particularly within the medical
cannabis arena. The Company's strategy is to identify early-stage
opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of
investee companies to a level where relevant time can be devoted to
each.